Here, we more closely evaluate, in an in vivo setting in immunocompetent mice, the checkpoints at which polyclonal Treg cells exert their inhibitory function. We evaluated the role of Treg cells in the well-characterized model of myelin oligodendrocyte glycoprotein (MOG)-induced EAE. As previous studies 9 have shown that administration of polyclonal Treg cell to normal mice can partially inhibit the development of EAE, we transferred into recipient mice either Treg cells that had been purified from normal mice and expanded in vitro by stimulation with

anti-CD3 and IL-2 or Treg cells that had been generated from Foxp3− T cells by stimulation in vitro with TGF-β. One day following transfer, the mice were immunized for the induction of EAE. Both groups of Treg cell-treated mice displayed significantly reduced clinical

severity www.selleckchem.com/products/Vorinostat-saha.html as compared with the control group (Fig. 1A, right panel). Endogenous Treg cells also control the development of EAE as mice treated with a partially depleting or inactivating anti-CD25 antibody 10 3 days prior to immunization consistently exhibited an exacerbated disease course (Fig. 1A, left panel). Overall, these studies demonstrate that merely altering the number of Treg cells KU-57788 research buy in vivo can dramatically alter the course of an autoimmune disease. To more thoroughly understand the mechanism(s) for the reduction of disease severity by enhancement of Treg cell numbers, we evaluated the phenotype of the Teff cells that had trafficked into the brain. We isolated the cellular infiltrate from the spinal cords of mice with EAE that had either received or had not received Treg cells, re-stimulated them in vitro with PMA/ionomycin, and evaluated cytokine production

by intracellular Selleck C59 staining. Mice that had received Treg cells had a two-fold reduction in the percentage of central nervous system infiltrating CD4+ Teff cells (Fig. 1B, top), but on a per cell basis, the cytokine profile of these cells was almost identical between the two groups (Fig. 1B, bottom; the two-fold difference in IFN-γ+IL-17+ cells was not a consistently reproducible result). No differences were observed in the production of IL-2, IL-4, or TNF-α, or in the expression of memory/activation markers such as CD44, CD25, or CD69 (data not shown). Thus, the reduced clinical disease most strongly correlates with the reduced percentage of Teff cells that invade the CNS rather than Treg cell-mediated inhibition of Th1/Th17 differentiation or induction of immune deviation leading to the development of a less pathogenic Th2 phenotype.